

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 6-K**

**Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

**For the month of June 2020**

**Commission File Number: 001-36622**

**PROQR THERAPEUTICS N.V.**

**Zernikedreef 9**

**2333 CK Leiden**

**The Netherlands**

**Tel: +31 88 166 7000**

(Address, Including ZIP Code, and Telephone Number,  
Including Area Code, of Registrant's Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

---

## **Annual General Meeting Results**

On June 23, 2020, **ProQR Therapeutics N.V.** (“**ProQR**” or the “**Company**”) held its annual general meeting of shareholders. The final results of each of the agenda items submitted to a vote of the shareholders are as follows:

Agenda Item 4: Adoption of the annual accounts for the financial year 2019.

ProQR shareholders approved the adoption of the annual accounts for the financial year 2019.

Agenda Item 5: Release from liability of the members of the Management Board with respect to the performance of their management during the financial year 2019.

ProQR shareholders approved the release from liability of the members of the Management Board with respect to the performance of their management during the financial year 2019.

Agenda Item 6: Release from liability of the members of the Supervisory Board with respect to the performance of their supervision during the financial year 2019.

ProQR shareholders approved the release from liability of the members of the Supervisory Board with respect to the performance of their supervision during the financial year 2019.

Agenda Item 7: Re-appointment of Supervisory Board member Dinko Valerio.

ProQR shareholders approved the re-appointment of Supervisory Board member Dinko Valerio.

Agenda Item 8: Re-appointment of Supervisory Board member James Shannon.

ProQR shareholders approved the re-appointment of Supervisory Board member James Shannon.

Agenda Item 9: Appointment of KPMG Accountants N.V. as the Company’s external auditor for the financial year 2021.

ProQR shareholders approved the appointment of KPMG Accountants N.V. as the Company’s external auditor for the financial year 2021.

Agenda Item 10: Amendment of the Company’s Equity Incentive Plan.

ProQR shareholders approved the amendment of the Company’s Equity Incentive Plan.

Agenda Item 11: Amendment of the compensation principles for the Supervisory Board.

ProQR shareholders approved the amendment of the compensation principles for the Supervisory Board.

Agenda Item 12: Amendment of the Compensation Policy for the Management Board.

ProQR shareholders approved the amendment of the Compensation Policy for the Management Board.

Agenda Item 13: Authorization of the Management Board to issue ordinary shares.

ProQR shareholders approved the authorization of the Management Board to issue ordinary shares.

Agenda Item 14: Authorization of the Management Board to acquire ordinary shares in the capital of the Company.

ProQR shareholders approved the authorization of the Management Board to acquire ordinary shares in the capital of the Company.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**PROQR THERAPEUTICS N.V.**

Date: June 24, 2020

By: /s/ Smital Shah  
Smital Shah  
Chief Financial Officer